(Q33378854)

26 July 2017

1 reference

title

Rituximab in the treatment of autoimmune haematological disorders (English)

1 reference

26 July 2017

1 reference

Bernadette Garvey

1

1 reference

26 July 2017

language of work or name

English

0 references

publication date

3 March 2008

1 reference

British Journal of Haematology

26 July 2017

published in

1 reference

26 July 2017

volume

141

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

149-169

1 reference

Rituximab-induced long-term remission in patients with refractory acquired hemophilia

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab for autoimmune haemophilia: a proposed treatment algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Acquired hemophilia: a case report of 2 patients with acquired factor VIII inhibitor treated with rituximab plus a short course of steroid and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab alone or in association with corticosteroids in the treatment of acquired factor VIII inhibitors: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Risk of infection and death among post-splenectomy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Childhood chronic immune thrombocytopenic purpura: unresolved issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Immune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

How I treat idiopathic thrombocytopenic purpura (ITP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Autoimmune hemolytic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Treatment with rituximab in benign and malignant hematologic disorders in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab therapy for refractory thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Factor VIII inhibitor associated with peginterferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Splenectomy for the treatment of thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Tolerability and safety of rituximab (MabThera).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Treatment of autoimmune hemolytic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Treating human autoimmune disease by depleting B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Acquired factor VIII inhibitors: pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab in postpartum-related acquired hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman's disease: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Pathogenic roles of B cells in human autoimmunity; insights from the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Treatment of chronic immune thrombocytopenic purpura: the patients' perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Outcomes in the treatment of thrombotic thrombocytopenic purpura with splenectomy: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

A dramatic response to rituximab in a patient with resistant thrombotic thrombocytopenic purpura (TTP) who developed acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Treatment of autoimmune hemolytic anemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Treatment of childhood autoimmune haemolytic anaemia with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Recent advances in thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Treatment of patients with acquired inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab in patients with refractory thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Autoimmune pathogenesis and autoimmune hemolytic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

The pathology of autoimmune haemolytic anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Thrombotic thrombocytopenic purpura and its diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Splenectomy for chronic idiopathic thrombocytopenic purpura in children: a single center study in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab in the treatment of acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Thrombotic Microangiopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AFTER RITUXIMAB IN A CASE OF NON-HODGKIN LYMPHOMA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

Thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07054.X

10.1111/J.1365-2141.2008.07054.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference